Advanced NIMBUS® Dressing Recognized as the Best Product-Oriented R&D Within Industry
Significantly Improved Wound Healing Results Reported at Wound Healing Society Meeting
GAINESVILLE, Fla., May 24, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the Wound Healing Society has again awarded its top Industrial Research and Development Award in recognition of scientific research at Quick-Med Technologies. This is the second time in the past six years that Quick-Med has earned the Society's top Industrial R&D recognition as the overall first place winner among all research abstracts. Presented at the society's Annual Meeting, this is Quick-Med's fifth Industrial Research and Development Award in that timeframe.
The Industrial Research and Development Award is presented by the Wound Healing Society to recognize the best product-oriented research and development being performed within the corporate world. The award, formerly known as the Blue Ribbon Industrial Research and Development Award, recognizes corporate research and development teams that are working to show mechanisms of action or efficacy for their company's products and technologies.
The Quick-Med Technologies' abstract is titled "Improved Healing in Weanling Pig Model of Vesicant Injury Shown by High Feature Antimicrobial Dressing" and can be viewed at: . The abstract presents the Company's latest work on an innovative new wound dressing that incorporates the unique and proprietary NIMBUS technology. This new dressing, NIMBUS® Advanced Active is the first "active" wound healing product in development by Quick-Med. It is a superabsorbent, non-leaching antimicrobial dressing that provides a moist wound healing environment plus the sustained release of active agents to promote optimum healing of burns and chemical blistering wounds. Specific agents used in this study were a growth factor, an antibiotic protease inhibitor (doxycycline) and antioxidant vitamins C and E.
The comprehensive in vivo animal experiments, which were conducted on behalf of Quick-Med by Battelle Memorial Institute, found that the NIMBUS-based dressings provided significantly improved wound healing compared to controls. Relative to controls, wounds treated with NIMBUS Advanced Active prototype dressings had more rapid formation of mature and well ordered dermal tissue with no scar tissue generation, and better structural support epidermis. In summary, the NIMBUS dressings show clear signs of better healing.
"This is an exciting implementation of our platform NIMBUS antimicrobial technology," said Dr. Jerry Olderman, Quick-Med's vice president of Research & Development. "We are truly honored that our research on accelerated healing of blistering wounds has been recognized by the Wound Healing Society. This is a wonderful tribute to our research team and the work we are doing to improve wound healing."
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
About the Wound Healing Society
The Wound Healing Society is a non-profit organization composed of clinical and basic scientists. Founded in 1990, the Society is recognized among professionals and government agencies as the leading scientific organization focused in the area of wound healing.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets. The Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial available in a wound dressing. Its NimbuDerm™ technology is being developed as a persistent hand sanitizer and its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see: www.quickmedtech.com.
The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260
© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at .
CONTACT: Quick-Med Technologies, Inc. Jerry Olderman, Ph.D., VP, R&D (888) 835.2211 Ext 104 firstname.lastname@example.org Stonegate Securities, Inc. Casey Stegman (investor/media contact) (214) 987-4121 email@example.com